RRR schreef op 2 januari 2013 22:32:
CSL Behring Launches Its First Co-Pay Assistance Program to Ease Financial Burden of Treating Hereditary Angioedema
Source Press Release
Company CSL Behring, CSL
Date January 02, 2013
CSL Behring Launches Its First Co-Pay Assistance Program to Ease Financial Burden of Treating Hereditary Angioedema
Berinert® Co-Pay BENefit covers up to $12,000 of patient's yearly out-of-pocket expenses
KING OF PRUSSIA, Pa., Jan. 2, 2013 /PRNewswire/ -- CSL Behring announced today the launch of a financial assistance program designed to cover patients' out-of-pocket expenses for Berinert®,C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute laryngeal, facial and abdominal attacks of hereditary angioedema (HAE). HAE is a rare and potentially fatal genetic disorder. BerinertCo-Pay BENefit is the most recent addition to the BerinertExpert Network (B.E.N.®), a full-service support program for healthcare providers and HAE patients and their caregivers. Berinert is available through specialty pharmacies and distributors in the United States.
Berinert Co-Pay BENefit assists with co-pay costs related to a patient's prescription for Berinert. On behalf of program participants, CSL Behring will coordinate with the patient's specialty pharmacy to cover the patient's out-of-pocket co-pay costs up to $12,000 in eligible expenses per year. The program is available to new or existing Berinertpatients, age 12 or older, who are U.S. residents insured in the U.S. and who receive product through a specialty pharmacy. Patients covered by state or federally funded programs, such as Medicare, Medicaid and Veterans Health Insurance, are not eligible.
"Berinert Co-Pay BENefit is the most recent example of CSL Behring's commitment to provide HAE patients and healthcare providers with quality products and comprehensive service and support programs," said Lynne Powell, Sr. VP of North American Commercial Operations. "For many hereditary angioedemapatients, enrollment in this program will increase their access to Berinert and result in no out-of-pocket expenses related to treatment."
In addition to Berinert Co-Pay BENefit, CSL Behring through B.E.N. provides information and assistance designed to help healthcare providers and HAE patients, including:
Comprehensive service and support on insurance and reimbursement – B.E.N. will help patients address such issues and questions as prior authorizations, coverage appeals, and letters of medical necessity
Patient Advocates for Learning and Support (PALS)– Through a peer-to-peer type program, HAE patient advocates share their experiences with new Berinert patients to help ease their transition onto therapy
Assurance and Assistance – The CSL Behring Assurance and Assistance Programs, working through B.E.N., ensure that:
Patients who experience a lapse in third-party, private health insurance can access Berinert
Qualified patients who are uninsured, underinsured or unable to afford their prescribed therapy can obtain Berinert
"As a person with HAE, I understand first-hand the difficulties patients experience dealing with confusing insurance reimbursement issues," said Janet Long, HAE patient and executive vice president of the Hereditary Angioedema Association. "As an organization, we are extremely grateful for programs that help ease the financial burden faced by HAE patients."
To enroll in the Berinert Co-Pay BENefit program, or for more information on B.E.N. 24 hours a day, seven days a week, call toll-free 1-877-BEN-4HAE (1-877-236-4423) or visit
www.Berinert.com.